ANNUAL REPORT AND ACCOUNTS for the year ended 30 June 2014 STRENGTHENING OUR POSITION WITHIN THE GLOBAL ANIMAL HEALTH MARKET 23481.04 9 September 2014 5:04 PM Proof 3 Welcome to Dechra Pharmaceuticals PLC Dechra is an international specialist veterinary pharmaceuticals and related products business.
Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide.
Our Strategy To continue to develop our position as an international, high margin, cash generative, specialist veterinary pharmaceuticals and related products business with a clear focus on key therapeutic areas: dermatology, ophthalmology, equine medicine, anaesthesia and analgesia, endocrinology, cardiovascular disease, food producing animal antimicrobials and pet diets through: Pipeline Portfolio Geographical Delivery Focus Expansion Acquisition a b c Investor website Curabitur quis eleifend mauris, at ultrices magna.
Investor Website We maintain a corporate website at Lorem ipsum dolor sit amet, consectetur www.
com containing a wide range of information of interest to both Adipiscing elit.
Donec sagittis mauris institutional and private investors including: Latest news and press releases Getting around the Report Annual reports and investor presentations Curabitur quis eleifend mauris, at ultrices magna duis interdum.
Look Out For These Icons Find out more about a specific topic View further content on our website: Scan the QR code with your smart www.
com device to visit our website.
Forward-Looking Statements: This document contains certain forward-looking statements.
The forward-looking statements reflect the knowledge and information available to the Company during preparation and up to the publication of this document.
By their very nature, these statements depend upon circumstances and relate to events that may occur in the future and thereby involving a degree of uncertainty.
Therefore, nothing in this document should be construed as a profit forecast by the Company.
A reconciliation to reported measures can be found on page 41.
Operational Highlights Approval of a major new equine product, Osphos, with Group revenue up by 1.6% CER : positive momentum in the launch targeted for quarter one of the 2015 financial year in second half with revenue growth of 4.0% CER.
Completed the acquisition of the trade and assets of PSPC Good progress on the pipeline: dossier submitted for approval Inc. which will expand our US product portfolio.
of a novel canine endocrine product in the US and EU.
Newly established Italian subsidiary opened in March 2014.
All EU markets are showing growth, with the exception of the Significantly improved net debt position of 5.0 million 2013: Netherlands.
80.8 million following divestment of the Services Segment.
Strong performance in the US driven by our key products growing well and the Ophthalmic range relaunch, partly offset by continuing supply issues.
